AstraZeneca: phase II trial on Covid drug misses target
(CercleFinance.com) - AstraZeneca said on Thursday that its Phase II trial of a blood cancer drug intended to treat patients hospitalised with respiratory symptoms of Covid-19 failed to meet its primary endpoint.
The company said that the addition of Calquence to best supportive care did not increase the proportion of patients who remained alive and free of respiratory failure in the studies.
Calquence is currently being developed for the treatment of multiple blood cancers, including leukaemia, and the trials were launched based on preclinical and early clinical evidence that the drug could decrease the hyperinflammatory immune response and improve clinical outcomes in hospitalised patients, the drugmaker said.
AstraZeneca shares were down 0.6% on the London Stock Exchange after these disappointing results.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The company said that the addition of Calquence to best supportive care did not increase the proportion of patients who remained alive and free of respiratory failure in the studies.
Calquence is currently being developed for the treatment of multiple blood cancers, including leukaemia, and the trials were launched based on preclinical and early clinical evidence that the drug could decrease the hyperinflammatory immune response and improve clinical outcomes in hospitalised patients, the drugmaker said.
AstraZeneca shares were down 0.6% on the London Stock Exchange after these disappointing results.
Copyright (c) 2020 CercleFinance.com. All rights reserved.